When was Glentham Life Sciences founded?

Glentham Life Sciences was founded in 2013.

Where is Glentham Life Sciences located?

Glentham Life Sciences is headquartered in Corsham, United Kingdom.

Which legal entities is Glentham Life Sciences associated with?

Glentham Life Sciences is associated with GLENTHAM LIFE SCIENCES LIMITED.

How many employees does Glentham Life Sciences have?

As of Aug 31, 2026, the latest employee count at Glentham Life Sciences is 16.

Where does Glentham Life Sciences rank among its competitors?

Glentham Life Sciences ranks 1813th amongst 1972 active competitors, of which 449 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was LifeMine Therapeutics, which secured $75M in Aug, 2026.

Who are the top competitors of Glentham Life Sciences?

Glentham Life Sciences' top competitors include Antheia, Transcenta and Akeso. Among them, LifeMine Therapeutics secured the most recent funding round in August, 2026.

Glentham Life Sciences - 2026 Company Profile, Team, Funding, Competitors & Financials

Glentham Life Sciences is a funded company based in Corsham (United Kingdom), founded in 2013 by Samuel White. It operates as a Supplier of life science products, fine chemicals & biochemicals. The company has 1972 active competitors, including 449 funded and 319 that have exited. Its top competitors include companies like Antheia, Transcenta and Akeso.

Company Details

Glentham Life Sciences is a UK based supplier of fine chemicals, biochemicals and life science products for the Diagnostics, Pharmaceutical, Research and Custom Synthesis markets. Its product ranges include Antibiotics, Amino Acids and derivatives, Carbohydrates and derivatives, Buffers and other biologic APIs. It is also certified with ISO 9001:2008 and offers a wide range of logistics services, including custom packaging, call-off orders and dangerous goods shipments.

Website: www.glentham.com/en/
Social
Email ID: *****@glentham.com

Key Metrics

Founded Year

2013

Location

Corsham, United Kingdom

Stage

Funding Raised

Investors

Castle Placement

Ranked

1813^th among 1972 active competitors

Employee Count

16 as on Aug 31, 2026

Similar Companies

Antheia & 2678 more

View Glentham Life Sciences' full profile

Glentham Life Sciences is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
GLENTHAM LIFE SCIENCES LIMITED CIN: 8553103 , United Kingdom, Active	Jun 02, 2013	-	29 (As on Jun 30, 2024)

Glentham Life Sciences is a funded company. Glentham Life Sciences has 1 institutional investor.

View details of Glentham Life Sciences's funding rounds and investors

The founders of Glentham Life Sciences is Samuel White.

Here are the details of Glentham Life Sciences' key team members:

Samuel White: Founder of Glentham Life Sciences.

View details of Glentham Life Sciences's Founder profiles and Board Members

Glentham Life Sciences' employee count trend

Glentham Life Sciences has 16 employees as of Aug 26. Here is Glentham Life Sciences's employee count trend over the years:

Employee count trend for Glentham Life Sciences

Uncover Glentham Life Sciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Glentham Life Sciences include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of Glentham Life Sciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
2nd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
3rd	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
4th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
5th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
6th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
7th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
8th	LifeMine Therapeutics 2016, Watertown (United States), Series E	Developer of novel drugs from fungi via genome mining and recombinant overexpression	$563M	Fidelity Investments, 6 Dimensions Capital ... & 17 others	62/100
9th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$364M	Maverick Ventures, SoftBank Vision Fund & 16 others	62/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
1813th	Glentham Life Sciences 2013, Corsham (United Kingdom), Funding Raised	Supplier of life science products, fine chemicals & biochemicals	-	Castle Placement	20/100